☆ 4.7 Letter

Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results

LEUKEMIA (2017)

Get Full Text
Add to Collection

Journal

LEUKEMIA
Volume 31, Issue 11, Pages 2529-2531

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/leu.2017.247

Keywords

-

Categories

Oncology Hematology

Funding

  1. Novartis Pharmaceuticals Corporation

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.